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Abstract
Background: Efflux has been recognized as a resistance mechanism to antimicrobials in Staphylococcus aureus;
however its role on the development of clinically relevant resistance is still poorly characterized. This study aimed to
examine the impact of efflux on development of resistance to fluoroquinolones and other antimicrobials in S.
aureus strains representing relevant phenotypes in terms of antibiotic susceptibility and efflux activity.
Methods: Two closely related methicillin- and ciprofloxacin-resistant Staphylococcus aureus clinical strains, with
different efflux capacity and the pan-susceptible strain ATCC25923 were exposed to constant concentrations of the
efflux pump (EP) substrates ciprofloxacin, ethidium bromide and cetrimide. Parental and exposed strains were
tested regarding their susceptibility towards antibiotics, biocides and ethidium bromide, efflux capacity and levels
of EP gene expression. Occurrence of resistance-associated mutations was screened by sequencing.
Results: Multidrug resistance phenotypes emerged upon exposure, independently of the substrate or its
concentration, which were correlated with increased efflux capacity of the exposed strains. The temporal pattern of
EP gene expression disclosed an early-response with high expression of several genes, followed by a late-response,
characterized by overexpression of specific genes. The overall cell response was more pronounced for strains with
an initial basal efflux activity. Remarkably, detection of the IS256 element in the promoter regions of mgrA and
norA, in some cases associated with increased gene expression, suggests that these genes may be hot spots for
IS256 insertion events.
The results obtained with exposure of ATCC25923 to ciprofloxacin were particularly striking, revealing a step-wise
development of fluoroquinolone resistance, with a first efflux-mediated response, followed by the occurrence of a
mutation in grlA that resulted in phenotypic resistance. Additionally, challenge by non-fluoroquinolone agents,
particularly cetrimide, promoted cross resistance to fluoroquinolones, revealing the potential role of biocides as
selective pressure for the emergence of resistance to these antibiotics.
Conclusions: This study reveals efflux as a significant component of S. aureus resistance to fluoroquinolones and
biocides and as a primary mechanism to withstand stress imposed by antimicrobials. This efflux-mediated response
can result in the emergence of multidrug resistance in healthcare environments and should be taken into account
in the management of this major pathogen.
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Background
S. aureus is a frequent human colonizer and major patho-
gen. Besides its pathogenicity and virulence potential, the
development and/or acquisition of resistance to antimi-
crobials (antibiotics and biocides) is of foremost import-
ance, as the occurrence of strains with a multidrug
resistance (MDR) phenotype is common. In particular,
methicillin-resistant S. aureus (MRSA) strains have be-
come a major problem in healthcare settings and in the
community [1] as they are generally associated with in-
creased burden regarding therapeutics and higher mortal-
ity rates than methicillin-susceptible S. aureus (MSSA)
strains [2, 3].
Fluoroquinolones target the S. aureus topoisomerase
IV (GrlA/B) and DNA gyrase (GyrA/B), inhibiting DNA
replication [4]. Resistance to these antibiotics emerges
swiftly and has been mainly attributed to the occurrence
of spontaneous mutations in the quinolone resistance-
determining region (QRDR) of the target genes grlA/B
and gyrA/B [4]. In Europe, around 25 % of invasive S.
aureus clinical isolates are resistant to fluoroquino-
lones, a rate that increases to almost 90 % among
MRSA isolates [5]. Although fluoroquinolones are not
used for the treatment of staphylococcal infections,
their intensive use in the hospital [6] has been pointed
out as a main selective factor for the emergence and
dissemination of fluoroquinolone resistance in S. aur-
eus, which, in turn, has been suggested to act as a se-
lective advantage for MRSA strains in comparison
with MSSA strains [7].
Resistance to fluoroquinolones may also arise by their
extrusion via efflux pumps (EPs) [8], as reported in S.
aureus clinical isolates [9–11] but considered clinically
non-relevant [12]. Several multidrug EPs have been iden-
tified in S. aureus, including NorA, NorB, NorC, MepA
and MdeA [13]. The few studies conducted to ascertain
their contribution to fluoroquinolone resistance have as-
sociated their activity to a reduced susceptibility to this
class of antibiotics [14–17]. Moreover, this same efflux
activity could be linked to decreased susceptibility to
additional antimicrobials such as biocides and dyes [14,
15, 18], highlighting the potential of these EPs to convey
a MDR phenotype to S. aureus strains.
Recent studies provided additional data supporting the
premise that efflux plays an important role in the emer-
gence of resistance to antimicrobials in bacteria. Indeed,
data from Escherichia coli and Mycobacterium tubercu-
losis demonstrate that efflux may be the cell’s first re-
sponse to cope with these compounds, allowing them to
endure their noxious effects until acquisition of a more
stable resistance mechanism, such as mutation, that will
then provide high-level resistance [19, 20]. Studies on
S. aureus also demonstrated the role of efflux as a first-
line defence mechanism towards noxious compounds
[21, 22], a hypothesis that has been confirmed in clin-
ical isolates [14–16, 23].
In this study, we aimed to highlight the relationship
between efflux and mutation(s) throughout the process
of emergence of resistance in S. aureus, by exposing a
set of representative MSSA and MRSA strains to sub-
inhibitory or inhibitory concentrations of antimicrobials
that are known substrates of MDR EPs: the fluoroquino-
lone ciprofloxacin (CIP), the biocide cetrimide (CET)
and the dye ethidium bromide (EtBr). The three strains
studied included a fully susceptible reference MSSA
strain and a pair of closely related clinical MRSA strains
resistant to ciprofloxacin, which carry the same set of
QRDR mutations but that differ in their efflux activity.
The expression of genes coding for the main MDR EPs
and their regulators was assessed at different time points
of exposure and correlated with the resistance level
towards fluoroquinolones and other antimicrobials
and the temporal acquisition of mutations.
Results
Exposure of MSSA and MRSA strains to fluoroquinolones
and biocides promotes a multidrug efflux response
The reference MSSA strain ATCC25923 and two clinical
MRSA strains, SM2 and SM50, belonging to ST2246-t037
(clonal complex 8), were each subjected to six different ex-
posure regimens for a period of 20-days: exposure to the
minimum inhibitory concentration (MIC) and to half
MIC of EtBr, CIP and CET (Additional file 1: Figure S1).
Bacterial growth was observed in the presence of the MIC
of each compound during day 1 of most exposure regi-
mens, albeit at different growth rates (data not shown),
probably due to: a) the different growth conditions used in
comparison to the MIC determination protocol and b) the
initial gradual physiological adaptation and survival of
bacteria to the MIC of the antimicrobial to which they
were exposed.
Occurrence of contaminations was ruled out by PFGE
analysis of SmaI macrorestriction profiles of the strains
before (P0) and after (P20) each exposure experiment
(Additional file 1: Figure S2).
Changes in the susceptibility profiles of the strains were
monitored by determination of MICs of the EP substrates
during exposure (Fig. 1, Additional file 1: Tables S1-S3).
We observed an overall MIC increase from two-fold to
16-fold, although exposure to the MIC did not always re-
sult in the highest levels of resistance (e.g., ATCC25923 or
SM50 exposed to CIP, Fig. 1b). EtBr and CIP promoted
higher MIC increases (mainly four- to 16-fold) than CET
(mostly two- to four-fold). The strains responsiveness to
the EP substrates differed according to their initial efflux
activity [14]; strains SM2 and ATCC25923 (with basal
efflux activity), showed higher MIC increases than strain
SM50 (higher initial efflux activity), which was the least
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Fig. 1 Evolution of MIC values (mg/L) of the EP substrates for the strains in study. The data presented correspond to the MICs of ethidium bromide
(EtBr, red), ciprofloxacin (CIP, green) and cetrimide (CET, blue) throughout the 20-day exposure to EtBr (a), CIP (b) and CET (c) at half MIC (dotted lines)
or at the MIC (full lines) (data available for days 0, 1, 2, 3 and 20th). No growth was obtained for strain SM50 at the CET concentration corresponding to
the MIC
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responsive strain. Moreover, absence of growth was ob-
served for strain SM50 exposed to the cetrimide MIC
(Fig 1c, Additional file 1: Table S3).
The data shown in Fig. 1 revealed that, in most cases,
the MIC increases occurred in the first days of exposure,
and in some conditions, more swiftly in the presence of
the MIC of the EP substrate (e.g., ATCC25923 exposed
to EtBr, Fig 1a). Strikingly, the three strains achieved
similar final MICs of EtBr and CET (32–64 mg/L and
4–8 mg/L, respectively) independently of the exposure
condition (EP substrate or its concentration). Of particu-
lar interest, exposure of strain ATCC25923 to each EP
substrate determined an increase in the MIC values of
fluoroquinolones, namely from 0.25 to 2 mg/L for CIP;
from 0.5 to ≥ 8 mg/L for norfloxacin and from 0.25 to
0.5-1 mg/L for levofloxacin, with the exception of expos-
ure to CET at half MIC (Additional file 1: Table S1). In
contrast, no significant alterations in susceptibility level
were found for the other antibiotics tested: oxacillin; peni-
cillin; vancomycin; chloramphenicol and tetracycline.
The exposure experiments also resulted in increased
resistance to the quaternary ammonium compounds cetyl-
pyridinium chloride, benzalkonium chloride and dequali-
nium chloride; to tetraphenylphosphonium bromide; to the
diamidine pentamidine and in a lesser extent to the bisbi-
guanidine chlorhexidine (Additional file 1: Tables S1-S3).
The next set of experiments confirmed that the MDR
phenotypes observed were associated with increased ef-
flux, as assessed by MIC determinations in the presence
of the efflux inhibitors thioridazine (TZ) (Table 1) and
verapamil (VER) (Additional file 1: Table S4). It has been
suggested that a four-fold MIC reduction in the presence
of an efflux inhibitor indicates inhibition of increased ef-
flux activity [14, 18, 24]. In this work, we observed that
TZ and VER were able to reduce the increased MICs of
EtBr, CIP and CET by two to 32-fold (Table 1, Additional
file 1: Table S4). This inhibitory effect was more pronounced
for strains ATCC25923 and SM2 exposed to EtBr.
The efflux activity of each exposed strain was further
evaluated by real-time fluorometry (Fig. 2). The slope of
each EtBr efflux curve was determined and correlated to
the rate of efflux, as well as the Relative Index of Efflux
activity (RIE), which corresponds to the exposed cells
overall capacity to efflux EtBr relatively to their original
status. The initial efflux activity of each strain is indicated
in orange in Fig. 2 and confirms that the initial basal and
naive efflux activity of both ATCC25923 and SM2 was
lower than that of SM50 (lower slope value). Most of the
conditions tested resulted in increased efflux activity, with
the exception of strains exposed to the sub-inhibitory
concentrations of CET and ATCC25923 exposed to
CIP. Also, in most cases, higher EtBr efflux (higher
RIE values and lower slope values) was detected with
the highest concentrations of substrate (Fig. 2).
Altogether, these data revealed that increased antimicro-
bial resistance in all the exposed strains correlates with an
augmented efflux capacity induced by the contact with
substrates of multidrug EPs.
Evaluation of EP gene expression levels
To ascertain which EPs were responsible for the induced
MDR phenotypes, we measured the expression levels of
the S. aureus MDR EP genes norA, norB, norC, mdeA
and mepA, as well as their regulatory genes mgrA and
mepR, at different stages of exposure. Changes in gene
expression were considered an early response when occur-
ring during day 1 of exposure, and a late response
when detected at day 20 (Fig. 3–5, Additional file 1:
Tables S5-S7).
Exposure to EtBr
Figure 3 and Additional file 1: Table S5 illustrate a simi-
lar genetic response for all strains to EtBr, consisting of
an early response with low overexpression levels of nor
genes (norB in ATCC25923 and SM50, and norA/B/C in
SM2), and a late response with reduction of expression
levels and/or a shift in the genes overexpressed (predom-
inant high expression of mepA and its regulator mepR).
This late and specific response via mepA/mepR genes
was consistently observed at half MIC of EtBr for the
three strains. In contrast, at the MIC, only ATCC25923
showed overexpression of norB and mepA/mepR whereas
in strains SM2 and SM50 only increased expression of
norA was detected.
Exposure to ciprofloxacin
A different genetic response was detected under expos-
ure to CIP (Fig. 4, Additional file 1: Table S6). Compared
to EtBr exposure, lower levels of gene expression were
found at either CIP concentration tested. An exception
was strain ATCC25923, which presented an early response
to the CIP MIC consisting of increased expression of all
genes, in particular mepA/mepR (Fig. 4, Additional file 1:
Table S6). In contrast, the two CIP-resistant strains SM2
and SM50 showed a predominance of nor genes overex-
pression in both early and late responses, which varied
with the concentration and over time (Fig. 4, Additional
file 1: Table S6).
Exposure to cetrimide
Exposure to CET also produced different patterns of gene
expression (Fig. 5, Additional file 1: Table S7). Strain
ATCC25923 presented a strong early response when ex-
posed to the MIC, with high levels of expression for all the
genes tested, while no changes in expression were seen on
exposure to half MIC. The two clinical strains had very dif-
ferent expression patterns. SM2 revealed a strong early re-
sponse, with increased expression of nearly all genes tested
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Table 1 Effect of TZ on EP substrates MICs before and after the exposure processes
MIC (mg/L) after exposure to:
EtBr CIP CET
Original MIC (mg/L) ½ MIC MIC ½ MIC MIC ½ MIC MIC
No EI + TZ No EI + TZ No EI + TZ No EI + TZ No EI + TZ No EI + TZ No EI + TZ
ATCC25923
EtBr 8 1 (↓8x) 32 4 (↓8x) 32 1 (↓32x) 32 8 (↓4x) 32 4 (↓8x) 8 2 (↓4x) 32 4 (↓8x)
CIP 0.25 0.125 (↓2x) 2 0.25 (↓8x) 2 0.25 (↓8x) 2 0.5 (↓4x) 2 0.5 (↓4x) 0.5 0.25 (↓2x) 2 0.5 (↓4x)
CET 2 0.25 (↓8x) 4 0.5 (↓8x) 8 0.125 (↓64x) 4 0.5 (↓8x) 4 0.5 (↓8x) 4 0.5 (↓8x) 4 0.5 (↓8x)
SM2
EtBr 8 2 (↓4x) 32 1 (↓32x) 64 2 (↓32x) 32 4 (↓8x) 32 2 (↓16x) 8 1 (↓8x) 32 4 (↓8x)
CIP 32 16 (↓2x) 128 16 (↓8x) 512 32 (↓16x) 256 32 (↓8x) 256 16 (↓16x) 32 8 (↓4x) 128 32 (↓4x)
CET 2 0.5 (↓4x) 4 0.25 (↓16x) 16 4 (↓4x) 4 2 (↓2x) 8 1 (↓8x) 4 0.5 (↓8x) 8 2 (↓4x)
SM50
EtBr 8 1 (↓8x) 64 8 (↓8x) 32 8 (↓4x) 64 4 (↓16x) 32 4 (↓8x) 16 2 (↓8x) — —
CIP 64 16 (↓4x) 256 64 (↓4x) 256 64 (↓4x) 512 64 (↓8x) 256 64 (↓4x) 128 32 (↓4x) — —
CET 4 0.5 (↓8x) 8 1 (↓8x) 8 1 (↓8x) 8 2 (↓4x) 8 2 (↓4x) 4 1 (↓4x) — —
The values in brackets correspond to the decrease (↓ n-fold) of the MICs in the presence of a sub-inhibitory concentration of TZ relatively to the original values (absence of efflux inhibitor); decreases of ≥ 4-fold are













Fig. 2 Assessment of EtBr efflux for the strains in study. Efflux capacity was evaluated at the beginning (orange) and at the end of the exposure
process to ethidium bromide (EtBr, red), ciprofloxacin (CIP, green) and cetrimide (CET, blue) at half MIC (dashed lines) and at the MIC (full lines).
All assays were conducted in the presence of 0.4 % glucose. EtBr-loaded cells were obtained by incubation with 200 mg/L of VER plus the following
EtBr concentrations: 0.125 mg/L (ATCC25923: P0, CIP(½MIC)_P20, CIP(MIC)_P20, CET(½MIC)_ P20; SM2: P0, CET(½MIC)_P20; SM50_CET(½MIC)_P20);
0.25 mg/L (ATCC25923: EtBr(½MIC)_P20, CET(MIC)_P20; SM2: CET(½MIC)_P20, CET(MIC)_P20; SM50: P0, EtBr(½MIC)_P20, EtBr(MIC)_P20, CIP(MIC)_P20);
0.5 mg/L (ATCC25923_EtBr(MIC)_P20; SM2: EtBr(½MIC)_P20, EtBr(MIC)_P20, CIP(MIC)_P20; SM50_CIP(½MIC)_P20). The data presented was normalized
against the data obtained in conditions of no efflux (dotted line, cells incubated without glucose in the presence of 200 mg/L of VER). The slope (m)
of the EtBr efflux curves was calculated by a linear regression of the values obtained in the first minutes of the assay and it relates to the rate
of EtBr efflux in each condition tested. The Relative Index of Efflux activity (RIE) values were calculated as described in Methods and allow the
direct comparison of the EtBr efflux activity of the strain after exposure (P20) to their initial efflux activity (P0)
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followed by a weak late response, mediated by mdeA or
norC, depending on the concentration used. Conversely,
SM50 showed only a low level overexpression of the nor
genes either in the early (norA) or late (norB/C) response.
Screening for the emergence of mutations associated
with resistance to fluoroquinolones
The occurrence of mutations associated with resistance
to fluoroquinolones was screened by analysis of the QRDR
of grlA and gyrA genes for the strains exposed to cipro-
floxacin. The CIP-susceptible strain ATCC25923 (MIC of
0.25 mg/L) contains a wild-type GyrA but carries a muta-
tion in GrlA, P144S, which has been reported for some S.
aureus isolates with a CIP MIC of 0.25 mg/L [17, 25], thus
not associated with resistance. This strain did not gain
mutations throughout exposure to half MIC of ciprofloxa-
cin. However, exposure to the ciprofloxacin MIC resulted
in an increased CIP MIC of 2 mg/L (Figs. 1 and 6, Table 1)
Fig. 3 Expression levels of EP and regulator genes of the strains in study during exposure to EtBr. Gene expression was measured in the presence
of EtBr at half MIC (orange) and at the MIC (blue) relatively to the drug-free growth condition. The results are presented as the mean and standard
deviation of at least two independent assays performed with total RNA. Overexpression was considered for values superior to 2 (cut-off value
represented by the green dashed line)
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and the acquisition of the mutation S80F in GrlA, while
GyrA remained unchanged. Screening of the grlA QRDR
of this strain in intermediate stages of the exposure
process revealed that this mutation occurred at day 5. This
mutation is one of the most commonly ascribed to GrlA
in S. aureus clinical isolates and has been associated with
ciprofloxacin resistance levels that vary between 2 and
12.5 mg/L [25, 26], corresponding to resistance according
to CLSI and EUCAST guidelines [27, 28].
Importantly, ATCC25923 strain also revealed a final
CIP MIC of 2 mg/L following exposure to EtBr and CET
(at the MIC) but without any detectable occurrence of
mutations in the QRDR of grlA/gyrA genes, indicating
that in these exposure conditions, the increased fluoro-
quinolone resistance was solely due to augmented efflux.
The CIP-resistant strains SM50 and SM2 already car-
ried by the time of their isolation a double mutation in
GrlA (S80F/E84K) accompanied by a single mutation in
Fig. 4 Expression levels of EP and regulator genes of the strains in study during exposure to CIP. Gene expression was measured in the presence
of CIP at half MIC (orange) and at the MIC (blue) relatively to the drug-free growth condition. The results are presented as the mean and standard
deviation of at least two independent assays performed with extracted total RNA. Overexpression was considered for values superior to 2 (cut-off
value represented by the green dashed line)
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GyrA (S84L), a combination associated with high level
resistance to ciprofloxacin (MICs ranging from 100 to >
800 mg/L) [26]. The QRDR region of their grlA/gyrA genes
was also sequenced after CIP exposure, but no additional
mutations were detected, indicating that the observed
increased resistance to fluoroquinolones (Figs. 1 and 6,
Additional file 1: Tables S1-S3) is solely attributable to in-
creased efflux activity, as confirmed by the results with ef-
flux inhibitors (Fig. 6, Table1 , Additional file 1: Table S4).
Screening for mutations in the strains exposed to EtBr
and CET also showed that no mutations occurred during
those exposure processes.
Screening for the emergence of mutations in norA and
mgrA promoters
The occurrence of mutations in the norA promoter region
has been frequently associated with norA overexpression
[15, 23]. Therefore, we screened for mutations in norA
Fig. 5 Expression levels of EP and regulator genes of the strains in study during exposure to CET. Gene expression was measured in the presence
of CET at half MIC (orange) and at the MIC (blue) relatively to the drug-free growth condition. The results are presented as the mean and standard
deviation of at least two independent assays performed with extracted total RNA. Overexpression was considered for values superior to 2 (cut-off
value represented by the green dashed line)
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promoter for exposed strains showing norA overexpres-
sion either in an early- or late-response. Different muta-
tions were encountered (Fig. 7), all already described by
other authors [23, 29, 30], which included the transitions
A→G and T→C and the transversion A→T, at posi-
tions −107, −89 and −94 (the nucleotide assigned to the
transcription initiation site) relatively to translation start.
A duplication event resulting in the insertion of the se-
quence CAATATAG in the −10 consensus motif was also
encountered. Of these mutations, only the transversion
A→T (−94) in strain SM2 exposed to CIP MIC and the
duplication event for strain SM50 exposed to the EtBr
Fig. 6 Effect of thioridazine on the ciprofloxacin MIC for the strains exposed to EP substrates. MIC values were determined for each strain prior to
exposure (P0) and after each exposure process (P20) in the absence (green columns) and in the presence (orange columns) of the efflux inhibitor
thioridazine (TZ) at the sub-inhibitory concentration of 12.5 mg/L. The strain ATCC25923 exposed to the ciprofloxacin MIC was the single one in
which a fluoroquinolone-resistance mutation (S80F in the QRDR region of GrlA) occurred during an exposure process (red star). The breakpoint
for considering intermediate resistance to ciprofloxacin (according to CLSI guidelines) is represented by a blue dashed line
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MIC were associated with norA overexpression at the
20th day of exposure.
An unexpected result was the independent detection
of the insertion element IS256 in the norA promoter re-
gion of strain SM2 upon exposure to the MIC of EtBr,
between the consensus motifs −35 and −10, and to the
MIC of CET, upstream of the promoter region and MgrA
binding sites, with a probable association with increased
norA expression only in the former. Rapid screening re-
vealed that no IS256 insertion had taken place in the pro-
moter regions of norB and norC in strain SM2, despite
detection of increased expression of these two genes (data
not shown).
No mutations were identified in the promoter region of
mgrA for mgrA overexpressing strains, although a copy of
IS256 was detected upstream of the mgrA putative pro-
moter region in unexposed SM2 and SM50 strains, which
may have affected mgrA expression and consequently, of
genes regulated by MgrA, namely norA/B/C.
Despite the observed overexpression of mepA/mepR of
strains ATCC25923 and SM2 exposed to EtBr, no muta-
tions were found in the promoter region of the mepRA
operon (data not shown). However, the mutation E32K
was detected in the regulator protein MepR for strain
SM2 exposed to EtBr, which may affect MepR function.
Discussion
Antimicrobial resistance is one of the most critical chal-
lenges of our time. Several studies have revealed that re-
sistance mediated by efflux is an important component
of antimicrobial resistance in S. aureus clinical isolates
[14–17]. The purpose of the present study was to dis-
close the impact of efflux on emergence of antimicrobial
resistance, by exploring the effect of different antimicro-
bials at different concentrations and times of exposure
in a group of representative strains, which included both
MSSA and MRSA strains. Our aim was to provide a bet-
ter understanding of the contribution of each multidrug
EP to resistance and to gain further insights in the
process of development of efflux-mediated resistance to
antimicrobials in S. aureus and its relationship with
mutation-based resistance. The study was restricted to
three representative, well characterized strains, in order to
allow a comprehensive interpretation of the patterns ob-
tained. The strains selected were S. aureus ATCC25923, a
fully susceptible reference strain, and two MRSA clinical
Fig. 7 Location of the norA promoter mutations found in norA overexpressing strains following antimicrobial exposure. The nucleotides are numbered
taking into consideration the norA starting codon. MgrA binding sites are identified by black lines. The consensus motifs −35 and −10 are also
identified in black lines. The symbol * identifies the nucleotide −132 (A) which is absent in SM2 and SM50 norA promoter sequence. The sites
of IS256 insertion within the norA promoter region of strain SM2 exposed to CET or EtBr MIC are also indicated (dotted arrows)
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strains that belong to a nosocomial clone that has been
detected in this major Lisbon hospital [31], ST2246-t037
(CC8), differing in their initial efflux activity [14, 18].
The results obtained clearly suggest that long-term
exposure of MSSA (ATCC25923) and MRSA (SM2 and
SM50) strains to the selected EP substrates resulted in
the development of a MDR phenotype, with increased
resistance to these agents as well as cross-resistance to
other antimicrobials (including norfloxacin, several qua-
ternary ammonium compounds and pentamidine). The
MDR phenotype emerged independently of the EP sub-
strate, its concentration and the strain’s initial susceptibil-
ity phenotype or efflux capacity.
The emergence of an efflux-mediated MDR phenotype
upon exposure to antimicrobials has also been observed
in previous studies [23, 24], showing that exposure to a
substrate of a multidrug EP promotes cross-resistance to
other substrates of the same EP. This behavior towards
selective pressure was also observed by Furi et al. [30].
One of the most important findings of this work was
that the challenge of a susceptible strain, ATCC25923,
by constant sub-inhibitory or inhibitory concentrations
of non-fluoroquinolone agents, particularly cetrimide,
promoted cross-resistance to fluoroquinolones, revealing
the potential role of these agents as a selective pressure
for the emergence of resistance to fluoroquinolones in
healthcare environments.
The genetic responsiveness of the strains to the differ-
ent EP substrates suggests a temporal differentiation in
the activation of MDR EP genes (cf. Fig. 3–5, Additional
file 1: Tables S5-S7). First, an early-response, occurring
throughout day 1 of exposure, where the strains responded
in a strong and non-specific manner by increasing the ex-
pression of several EP genes. This was followed by a more
specific late-response, which occurred following prolonged
exposure to the stimulus, in which the number of EP genes
overexpressed and/or their level of expression decreased.
This reduction in expression levels may occur because the
number of EP proteins in the cell membrane required to
cope with the antimicrobials may have reached a max-
imum value, suggesting that the reduced expression level
observed at day 20 may be the necessary to compensate
for protein turnover.
In a closer look, different patterns of gene expression
were found. Some genes were predominantly overex-
pressed upon exposure to EtBr and CIP (mepA and the
nor genes, respectively), in accordance with the substrate
profile described for these MDR EPs [13]. Regarding
CET, a preferable expression pattern of EP genes could
not be established since a strong response with several
genes was observed. This non-specific response may re-
flect the broader effect that this membrane-active com-
pound exerts upon the bacterial cell [32], which triggers
a global stress response. A correlation between the
substrate concentration and increased gene expression
was only observed for strain ATCC25923, which was in-
dependent of the substrate. For the clinical strains SM2
and SM50, increasing concentrations of EP substrates
did not result in a stronger nor earlier response.
Although the results obtained for these three strains
cannot be over generalized, they clearly show an overall
pattern of S. aureus responsiveness upon challenge with
antimicrobials, which is efflux driven and build upon
each strain characteristics and may assist the design of
future studies on antimicrobial resistance prevention. This
overall response was less pronounced for SM50, the only
strain which presented an initial well-established increased
efflux activity. This difference translated in the distinct be-
haviour of both clinical strains in response to EtBr and
CET. While strain SM2 presented a strong early response
with overexpression and de novo expression of several EP
genes, the response of SM50 was comparably weaker (cf.
Fig. 3–5). This dissimilar behavior is particularly striking
as these are very closely related strains, as demonstrated
by PFGE analysis and illustrates the multiple efflux-
mediated responses that S. aureus can display within
the same lineage, a finding in contrast to results from
other studies [33]. Regarding the response to CIP, both
strains (already carrying QRDR mutations conferring high-
level resistance) showed mild values of EP gene overex-
pression, which may account for the additional level of
resistance attributed to efflux. Previous data suggested
that clinical strains are primed to efflux noxious com-
pounds, a trait that may be attributable to their prior ex-
posure to antimicrobials in the hospital environment [14].
The susceptible reference strain ATCC25923, with an ini-
tial basal efflux activity, presented a behavior similar to
SM2, with strong responses to all three substrates. This is
a prototype strain with no prior exposure to antimicro-
bials and not primed for efflux, thus requiring higher
levels of EP gene expression to cope with the noxious
agents. In a previous work, exposure of ATCC25923 to
EtBr triggered a preferred induction of the norA gene [24],
whereas in the present study a MepA-mediated response
to EtBr was noted. This difference could be due to the
different exposure methodology used (exposure to con-
stant versus step-wise, increasing EtBr concentrations).
These data support previous findings suggesting that the
same strain may respond to the same substrate via differ-
ent efflux systems, depending on the concentration of the
substrate and time of contact [14, 23].
Screening for mutations in norA promoter region re-
vealed that stable norA overexpression was correlated
with the occurrence of mutations in its promoter region.
Most striking, we could also observe the insertion of the
IS256 element in the norA and mgrA promoter regions,
although not always associated with increased gene ex-
pression. Multiple IS256 transpositions have been observed
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in the genome of S. aureus and correlated with reduced
susceptibility to vancomycin, as a copy of IS256 was found
in the promoter region of genes associated with glycopep-
tide resistance originating hybrid promoters, probably
responsible for an increased gene expression [34]. Other
studies have also shown that exposure to antibiotics such
as CIP, vancomycin, chloramphenicol, linezolid and spec-
tinomycin activates spontaneous transposition of IS256
which could be associated with a decrease of antibiotic
susceptibility [35–37]. Moreover, it has been shown that
IS256 insertion in the promoter regions of the genes mecA
in Staphylococcus sciuri [38] and llm in S. aureus [39] is
involved in higher transcription rates of both genes with a
concomitant increased resistance to methicillin. In this
study, we show that exposure to non-antibiotics may also
activate spontaneous transposition of IS256 and that norA
and mgrA promoters may be hot spots for IS256 insertion
, an event that, to our knowledge, is here described for the
first time, further supporting the important role of efflux
on the global S. aureus stress response.
The evolution of the susceptibility profile and gene
expression analysis upon exposure demonstrated that
efflux is a first-line response to antimicrobials. For the
two clinical strains, it was demonstrated that efflux is an
important component of resistance as these ciprofloxacin-
resistant strains, harboring resistance mutations prior to
exposure, became even more resistant to these antibiotics,
not by acquiring additional mutations but by increasing
their efflux activity. This observation was empathized by
the inclusion of a fully susceptible reference strain for
which the acquisition of fluoroquinolone resistance muta-
tions follows the activation of EPs, which confer a low but
clinically significant level of resistance that allows survival
of bacteria even under MIC exposure. Significantly, this
same resistance phenotype could be achieved by exposure
to non-fluoroquinolone antimicrobials. These findings pro-
vide further evidence that efflux is an important player in
the emergence of fluoroquinolone resistance in S. aureus.
Conclusions
The last decade witnessed a growing awareness of the
clinical importance of efflux as a mechanism of resistance
to antimicrobial compounds. In recent years, a new per-
spective on the role played by MDR efflux systems has
been emphasized, which are now perceived as important
players in the emergence of resistance in bacteria [40]. In
addition, a wide number of toxic compounds have been
identified as substrates of these systems [41]. The findings
of this study show that MDR EP substrates, including
fluoroquinolones and biocides, compounds that are com-
monly used in hospital environments, promote a physio-
logical response by S. aureus, which is based on efflux and
persists over time with the maintenance of the stimulus.
In the case of the pan-susceptible ATCC25923 strain, this
efflux-mediated response resulted in detectable resistance
to fluoroquinolones, in a step-wise process; a first step
with activation of multidrug EP genes followed by a sec-
ond step with acquisition of QRDR mutations. These
are promising results, as they establish the key role of ef-
flux in the first-line response to these antimicrobial
agents until more stable and efficient forms of resist-
ance appear. Moreover, they suggest that exposure to
non-fluoroquinolone agents may act as selective pres-
sure for the maintenance and dissemination of fluoro-
quinolone resistance, reportedly a selective factor for
the persistence of MRSA strains in the hospital [7].
Methods
Bacterial strains
S. aureus ATCC25923 is a fully susceptible reference strain
used as control in susceptibility testing while SM50 and
SM2 are representative MRSA strains, from a collection
of 52 ciprofloxacin-resistant S. aureus clinical isolates,
originating from a 1, 300-bed teaching hospital in Lisbon,
Portugal [14]. The SM50 and SM2 strains are genetically
related, differing in their macrorestriction PFGE patterns
in the size of a single SmaI-fragment of ca. 400 kb; in
addition these strains carry the same set of QRDR mu-
tations in GrlA (S80F/E84K) and GyrA (S84L) [14, 18].
Despite these similarities, SM50 shows a higher fluoro-
quinolone resistance level, previously correlated with
an increased efflux activity, which was also associated with
increased resistance to biocides and EtBr. In comparison,
strains SM2 and ATCC25923 have been previously char-
acterized as presenting only basal efflux activity [14, 18].
Antimicrobials and efflux inhibitors
The compounds were acquired from different sources, as
follows: CIP (ciprofloxacin), levofloxacin, chlorhexidine
diacetate (Fluka Chemie GmbH, Buchs, Switzerland);
norfloxacin, oxacillin, penicillin, vancomycin, chloram-
phenicol, tetracycline, EtBr (ethidium bromide), CET
(cetrimide), pentamidine isothionate salt, cetylpyridinium
chloride, benzalkonium chloride, tetraphenylphosphonium
bromide, chlorhexidine digluconate, dequalinium chloride,
VER (verapamil) and TZ (thioridazine) (Sigma-Aldrich, St.
Louis, MO, USA). Stock solutions were prepared in deion-
ized water, with the exception of tetracycline and chloram-
phenicol, prepared in 95 % ethanol. All solutions were
prepared on the day of the experiment and kept protected
from the light.
Determination of MICs
Cultures were grown in Mueller-Hinton broth (Oxoid Ltd.,
Basingstoke, UK) at 37 °C. MICs of antibiotics were deter-
mined by the two-fold broth microdilution method and
evaluated according to the CLSI breakpoints [27]. MICs of
biocides and dyes were also determined using the two-fold
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broth microdilution method during an18 h incubation
period at 37 °C.
MICs in the presence of efflux inhibitors
The inhibitory effect of the efflux inhibitors TZ and VER
on the susceptibility of the EP substrates CIP, CET and
EtBr was evaluated by the two-fold microdilution method
in the same conditions but in medium containing add-
itionally a sub-inhibitory concentration of the efflux in-
hibitor, guaranteeing no effect on cell viability, as follows:
12.5 mg/LTZ and 200 mg/L VER [14]. After an 18 h incu-
bation period at 37 °C, the presence of bacterial growth
was evaluated visually and the lowest concentration of
antimicrobial that presented no visible growth was regis-
tered as the MIC. All assays were performed in triplicate.
Exposure procedure
Strains ATCC25923, SM2 and SM50 were serially ex-
posed during 20 days to constant concentrations
equivalent to half their MIC or the MIC value of the EP
substrates EtBr, CIP or CET (Additional file 1: Figure S1).
Cultures were grown overnight in tryptone soy broth (P0)
(TSB, Oxoid) and then diluted 100-fold in TSB (control)
or in TSB supplemented with the EP substrates, consider-
ing the following MICs: EtBr, 6.25 mg/L (ATCC25923)
and 8 mg/L (SM2, SM50); CIP, 0.25 mg/L (ATCC25923),
32 mg/L (SM2) and 64 mg/L (SM50); CET, 2 mg/L
(ATCC25923, SM2), 4 mg/L (SM50). The cultures were
incubated at 37 °C with shaking and after 18 h an aliquot
was diluted 100-fold in media supplemented with the same
concentration of the substrate and grown in the same con-
ditions. This procedure was repeated through 20 passages
in 20 days (P20), after the first culture (P1) was obtained.
The response of the strains to each EP substrate was moni-
tored at several time points by MIC determination to EP
substrates (P0 – P3, P20) and to a wide panel of antibiotics
and biocides (P0, P20) in the absence and presence of ef-
flux inhibitors (Additional file 1: Figure S1).
PFGE analysis of SmaI macrorestriction profiles
The identity of strains before (P0) and after (P20) anti-
microbial exposure was verified by PFGE analysis of SmaI
macrorestriction profiles using a previously described
protocol [14, 42].
Assessment of EtBr efflux activity by real-time- fluorometry
This method allows the real-time fluorometric detection
of EtBr efflux, a broad substrate of bacterial EPs [43].
The capacity of cells to efflux EtBr was evaluated as de-
scribed previously [14]. Briefly, EtBr-loaded cells were
obtained by incubation with 200 mg/L of VER (the efflux
inhibitor that promotes the highest EtBr accumulation
in S. aureus) [14] and the most suitable EtBr concentra-
tion for each culture. Efflux assays in EtBr-loaded cells
were then conducted in the presence and absence of
VER 200 mg/L and/or glucose at 0.4 % (see details in le-
gend of Fig. 2). EtBr efflux was monitored in a Rotor-
Gene 3000™ during a period of 10 min with detection of
fluorescence at 535/585 nm each 10 seconds. For each
assay, the raw data obtained was normalized against data
of non-effluxing cells (cells plus 200 mg/L VER only), at
each point, considering that these correspond to the
maximum fluorescence values that can be achieved dur-
ing the assay. The relative fluorescence thus corresponds
to the ratio of fluorescence that remains per unit of
time, relatively to the EtBr-loaded cells [43]. The slope
(m) of each resulting EtBr efflux curve was calculated by
linear regression using the values obtained during the
first 1 to 2 min of the assays, as they portray the linear
behavior of the EtBr extrusion from the cells reflecting
the efflux responsiveness of each strain. The Relative
Index of Efflux activity (RIE) was calculated using the
following formula:
RIE ¼ RF of cells at P20ð Þ− RF of cells at P0ð Þ
RF of cells at P0ð Þ
Where RF is the relative fluorescence value at the 10th
minute of the efflux assay and P0 and P20 correspond to
day 0 and day 20, respectively, of exposure. The RIE
values allow a direct comparison of the EtBr efflux activ-
ity of each strain after exposure relatively to its initial
condition, with a value of 0 corresponding to no increase
in efflux activity and a value of 1 corresponding to a 100 %
increase of EtBr efflux. Negative RIE values represent loss
of EtBr efflux activity.
Gene expression analysis
The expression of the multidrug EP genes norA, norB,
norC, mepA, mdeA and of the regulator genes mgrA and
mepR was evaluated during day 1 (at mid exponential
growth phase (OD600 of 0.6) and at the 18
th h of growth)
and day 20 (18th h of growth) of exposure (Additional
file 1: Figure S1). At these time points, a 2 mL aliquot of
culture was transferred to a mixture of 1:1 acetone:ethanol
and immediately kept at −20 °C for RNA extraction. Total
RNA was isolated by the Trizol method [44] using TRI re-
agent (Sigma). RNA was quantified in a NanoDrop 1000
(ThermoScientific, Madison, WI, USA) and its integrity
evaluated by 1 % agarose-2.2 M formaldehyde gel electro-
phoresis. Quantitative RT-PCR (RT-qPCR) was performed
using the QuantiTect SYBR Green RT-PCR Kit (QIAGEN,
Hilden, Germany) in a Rotor-Gene 3000™ thermocycler
and equivalent RNA quantities. The primers used in these
assays are described in Additional file 1: Table S8. Relative
gene expression was assessed by comparison of the
relative quantity of each mRNA in the presence of EP
substrate to the control (substrate-free condition of the
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corresponding time point) using the comparative thresh-
old cycle (CT) method [45] and by using gyrB gene as ref-
erence control, with real-time analysis software. Negative
and genomic DNA contamination controls were included.
Genes showing increased expression of at least two-fold
were considered to be overexpressed. To verify the reac-
tion specificity, a melting curve analysis was done after
each assay and the RT-qPCR products were visualized in a
2 % agarose gel electrophoresis.
Screening of resistance mutations in grlA/gyrA genes and
promoter regions of norA/B/C and mgrA
Genomic DNA was isolated with the QIAamp DNA Mini
Kit (QIAGEN), with an additional step of 30 min digestion
with 0.2 mg/L of lysostaphin (Sigma) prior to extraction.
Internal fragments comprising the QRDR of grlA (GrlA
residues 14–181) and gyrA (GyrA residues 14–186) genes
and fragments comprising the promoter regions of
genes norA/B/C and mgrA were amplified using the
primers described in Additional file 1: Table S8. Amp-
lification products were sequenced in both strands
using the same set of primers. Sequences were analyzed
and aligned using the freeware programs BioEdit and
ClustalOmega, respectively.
Multilocus sequence typing (MLST)
Internal fragments of the seven housekeeping genes arcC,
aroE, glpF, gmk, pta, tpi and yqiL were amplified by PCR
using the primers and conditions described previously
[46, 47]. The PCR products were then sequenced on both
strands using the same set of primers. The sequences were
submitted to the MLST database (www.mlst.net) in order
to obtain an allelic profile and sequence type (ST).
spa typing
An internal fragment of the spa gene was amplified using
established primers [48]. The amplified products were se-
quenced and the sequences submitted to the spaTyper
free software (http://spatyper.fortinbras.us) in order to as-
sign spa types.
Availability of supporting data
The data sets supporting the results of this article are in-
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Additional data for the strains in study containing MIC values of
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gene expression of MDR EP and regulator genes at different time points
of exposure to the EP substrates (Tables S5 to S7); list of the primers
used in this study (Table S8); diagram of the exposure processes to
which the three strains were subjected (Figure S1); SmaI macrorestriction
profiles of the parental and exposed strains (Figure S2). (DOCX 1137 kb)
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